AI-generated from publicly available materials.Ghent's SpectaCell has officially launched with €6 million in Seed funding to enhance cell analysis for immunotherapy development.
The startup, emerging from imec, VIB, and Ghent University, aims to revolutionize cell therapy analytics. Led by imec.xpand, the funding round also saw contributions from PMV’s Flanders Future Tech Fund, InnovationQuarter Capital, Qbic, and VIB. CEO Tony Montoye emphasized the need for advanced tools to help researchers identify promising drug candidates earlier in the process, thereby expediting the development of effective treatments.
Founded in 2026 by a team of experts, SpectaCell is focused on creating a next-generation platform that utilizes digital imaging and data analytics to assess treatment impacts on individual cells. The company addresses significant challenges in immunotherapy, particularly the need for clearer insights into treatment effects, which can often be obscured by traditional testing methods that rely on averages. Their technology allows for high-resolution tracking of cell interactions without the interference of fluorescent labels, providing rapid results that can enhance decision-making in drug development.
Targeting pharmaceutical and biotech companies globally, SpectaCell's platform is designed for comprehensive use, from early research phases to routine quality checks in manufacturing. With plans to leverage the new funding for further development and commercialization, the company aspires to set a new standard in the industry, potentially transforming how new medicines are evaluated and produced.